Relation between methylmercury exposure and plasma paraoxonase activity in inuit adults from nunavik

Environmental Health Perspectives

Volumn 119, Issue 8, 2011, Pages 1077-1083

  Ayotte, Pierre ^a,b   Carrier, Antoine ^a   Ouellet, Nathalie ^a,b   Boiteau, Véronique ^a   Abdous, Belkacem ^a   Sidi, Elhadji Anassour Laouan ^a   Château Degat, Marie Ludivine ^a   Dewailly, Éric ^a  

^a LAVAL UNIVERSITY   (Canada)

^b INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

Author keywords

Inuit; Methylmercury; Nunavik; Omega 3 polyunsaturated fatty acids; Paraoxonase; PON1; Selenium

Indexed keywords

ARYLDIALKYLPHOSPHATASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; METHYLMERCURY; OMEGA 3 FATTY ACID; SELENIUM;

ADULT; AGE; AGED; ARTICLE; BLOOD LEVEL; CANADA; CROSS-SECTIONAL STUDY; DIETARY INTAKE; ENZYME BLOOD LEVEL; ERYTHROCYTE MEMBRANE; ESKIMO; FEMALE; FOOD CONTAMINATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MALE; MASS SPECTROMETRY; MERCURY BLOOD LEVEL; PLASMA PARAOXONASE ACTIVITY; PRIORITY JOURNAL; SEA FOOD; SELENIUM BLOOD LEVEL;

ADOLESCENT; ADULT; AGED; ARYLDIALKYLPHOSPHATASE; CHOLESTEROL, HDL; ERYTHROCYTE MEMBRANE; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; INUITS; LEAD; MALE; METHYLMERCURY COMPOUNDS; MIDDLE AGED; REGRESSION ANALYSIS; SELENIUM; YOUNG ADULT;

EID: 79961056479     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.1003296     Document Type: Article

References (44)

1. Aviram M. 2000. Review of human studies on oxidative damage and antioxidant protection related to cardiovascular diseases. Free Radic Res 33(suppl):S85-S97.
2. Bang HO, Dyerberg J, Nielsen AB. 1971. Plasma lipid and lipoprotein pattern in Greenlandic West-coast Eskimos. Lancet 1:1143-1145.
3. Boesch-Saadatmandi C, Rimbach G, Schrader C, Kofler BM, Armah CK, Minihane AM. 2010. Determinants of paraoxonase activity in healthy adults. Mol Nutr Food Res 54:1842-1850.
4. Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE. 2001. Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet 68:1428-1436.
5. Carvalho CM, Chew EH, Hashemy SI, Lu J, Holmgren A. 2008. Inhibition of the human thioredoxin system. A molecular mechanism of mercury toxicity. J Biol Chem 283:11913-11923.
6. Château-Degat ML, Dewailly É, Louchini R, Counil E, Noel M, Ferland A, et al. 2010. Cardiovascular burden and related risk factors among Nunavik (Quebec) Inuit: insights from baseline findings in the circumpolar Inuit health in transition cohort study. Can J Cardiol 26:190-196.
7. Cherki M, Berrougui H, Isabelle M, Cloutier M, Koumbadinga GA, Khalil A. 2007. Effect of PON1 polymorphism on HDL antioxidant potential is blunted with aging. Exp Gerontol 42:815-824.
8. Cole TB, Li WF, Richter RJ, Furlong CE, Costa LG. 2002. Inhibition of paraoxonase (PON1) by heavy metals [Abstract]. Toxicol Sci 66(suppl 1):312.
9. Corcoran AC, Rabinowitch IM. 1937. A study of the blood lipoids and blood protein in Canadian eastern Arctic Eskimos. Biochem J 31:343-348.
10. Costa LG, Vitalone A, Cole TB, Furlong CE. 2005. Modulation of paraoxonase (PON1) activity. Biochem Pharmacol 69:541-550.
11. Counil E, Julien P, Lamarche B, Chateau-Degat ML, Ferland A, Dewailly É. 2009. Association between trans-fatty acids in erythrocytes and pro-atherogenic lipid profiles among Canadian Inuit of Nunavik: possible influences of sex and age. Br J Nutr 18:1-11.
12. Debord J, Bollinger JC, Merle L, Dantoine T. 2003. Inhibition of human serum arylesterase by metal chlorides. J Inorg Biochem 94:1-4.
13. Ferré N, Camps J, Fernandez-Ballart J, Arija V, Murphy MM, Ceruelo S, et al. 2003. Regulation of serum paraoxonase activity by genetic, nutritional and lifestyle factors in the general population. Clin Chem 49:1491-1497.
14. Ferré N, Camps J, Marsillach J, Mackness B, Mackness M, Coll B, et al. 2005. Comparison of paraoxonase 1 measurements in serum and in lithium-heparin-anticoagulated plasma samples. Clin Chem 51:922-923.
15. Fontaine J, Dewailly É, Benedetti JL, Pereg D, Ayotte P, Déry S. 2008. Re-evaluation of blood mercury, lead and cadmium concentrations in the Inuit population of Nunavik (Québec): a cross-sectional study. Environ Health 7:25;doi:10.1186/1476-069X-7-25 [Online 2 June 2008].
16. Gençer N, Arslan O. 2009. Purification human PON1Q192 and PON1R192 isoenzymes by hydrophobic interaction chromatography and investigation of the inhibition by metals. J Chromatogr B Analyt Technol Biomed Life Sci 877:134-140.
17. Gonzalvo MC, Gil F, Hernandez AF, Villanueva E, Pla A. 1997. Inhibition of paraoxonase activity in human liver microsomes by exposure to EDTA, metals and mercurials. Chem Biol Interact 105:169-179.
18. Grotto D, de Castro MM, Barcelos GR, Garcia SC, Barbosa F Jr. 2009. Low level and sub-chronic exposure to methylmercury induces hypertension in rats: nitric oxide depletion and oxidative damage as possible mechanisms. Arch Toxicol 83:653-662.
19. Harris WS, Von Schacky C. 2004. The omega-3 index: a new risk factor for death from coronary heart disease? Prev Med 39:212-220.
20. Jaouad L, de Guise C, Berrougui H, Cloutier M, Isabelle M, Fulop T, et al. 2006. Age-related decrease in high-density lipoproteins antioxidant activity is due to an alteration in the PON1's free sulfhydryl groups. Atherosclerosis 185:191-200.
21. Jarvik GP, Rozek LS, Brophy VH, Hatsukami TS, Richter RJ, Schellenberg GD, et al. 2000. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler Thromb Vasc Biol 20:2441-2447.
22. Jarvik GP, Tsai NT, McKinstry LA, Wani R, Brophy VH, Richter RJ, et al. 2002. Vitamin C and E intake is associated with increased paraoxonase activity. Arterioscler Thromb Vasc Biol 22:1329-1333.
23. Jayakumari N, Thejaseebai G. 2009. High prevalence of low serum paraoxonase-1 in subjects with coronary artery disease. J Clin Biochem Nutr 45:278-284.
24. Jorgensen ME, Bjerregaard P, Kjaergaard JJ, Borch-Johnsen K. 2008. High prevalence of markers of coronary heart disease among Greenland Inuit. Atherosclerosis 196:772-778.
25. Khan MA, Wang F. 2009. Mercury-selenium compounds and their toxicological significance: toward a molecular understanding of the mercury-selenium antagonism. Environ Toxicol Chem 28:1567-1577.
26. Kjaergaard M, Andersen S, Holten M, Mulvad G, Kjaergaard JJ. 2009. Low occurrence of ischemic heart disease among Inuit around 1963 suggested from ECG among 1851 East Greenland Inuit. Atherosclerosis 203:599-603.
27. Lepage G, Roy CC. 1988. Specific methylation of plasma nonesterified fatty acids in a one-step reaction. J Lipid Res 29:227-235.
28. Li WF, Pan MH, Chung MC, Ho CK, Chuang HY. 2006. Lead exposure is associated with decreased serum paraoxonase 1 (PON1) activity and genotypes. Environ Health Perspect 114:1233-1236.
29. Lin TH, Huang YL, Huang SF. 2006. Lipid peroxidation in liver of rats administrated with methyl mercuric chloride. Biol Trace Elem Res 54:33-41.
30. Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, et al. 2001. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 21:1451-1457.
31. Mackness B, Durrington P, McElduff P, Yarnell J, Azam N, Watt M, et al. 2003. Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study. Circulation 107:2775-2779.
32. Mackness MI, Mackness B, Durrington PN, Fogelman AM, Berliner J, Lusis AJ, et al. 1998. Paraoxonase and coronary heart disease. Curr Opin Lipidol 9:319-324.
33. Ragunathan N, Busi F, Pluvinage B, Sanfins E, Dupret JM, Rodrigues-Lima F, et al. 2010. The human xenobioticmetabolizing enzyme arylamine N-acetyltransferase 1 (NAT1) is irreversibly inhibited by inorganic (Hg2+) and organic mercury (CH3Hg+): mechanism and kinetics. FEBS Lett 584:3366-3369.
34. Rayman MP. 2009. Selenoproteins and human health: insights from epidemiological data. Biochim Biophys Acta 1790:1533-1540.
35. Salonen JT, Seppanen K, Nyyssonen K, Korpela H, Kauhanen J, Kantola M, et al. 1995. Intake of mercury from fish, lipid peroxidation, and the risk of myocardial infarction and coronary, cardiovascular, and any death in eastern Finnish men. Circulation 91:645-655.
36. Seres I, Paragh G, Deschene E, Fulop T Jr, Khalil A. 2004. Study of factors influencing the decreased HDL associated PON1 activity with aging. Exp Gerontol 39:59-66.
37. Shaikh NA, Downar E. 1981. Time course of changes in porcine myocardial phospholipid levels during ischemia. A reassessment of the lysolipid hypothesis. Circ Res 49:316-325.
38. Shih DM, Xia YR, Wang XP, Miller E, Castellani LW, Subbanagounder G, et al. 2000. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem 275:17527-17535.
39. Sorenson RC, Primo-Parmo SL, Kuo CL, Adkins S, Lockridge O, La Du BN. 1995. Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase. Proc Natl Acad Sci USA 92:7187-7191.
40. Stern AH. 2005. A review of the studies of the cardiovascular health effects of methylmercury with consideration of their suitability for risk assessment. Environ Res 98:133-142.
41. Tremblay AJ, Morrissette H, Gagné JM, Bergeron J, Gagné C, Couture P. 2004. Validation of the Friedewald formula for the determination of low-density lipoprotein cholesterol compared with beta-quantification in a large population. Clin Biochem 37:785-790.
42. Varatharajalu R, Garige M, Leckey LC, Gong M, Lakshman MR. 2010. Betaine protects chronic alcohol and omega-3 PUFA-mediated down-regulations of PON1 gene, serum PON1 and homocysteine thiolactonase activities with restoration of liver GSH. Alcohol Clin Exp Res 34:424-431.
43. Yang WI, Lee SH, Ko YG, Kang SM, Choi D, Ha JW, et al. 2010. Relationship between paraoxonase-1 activity, carotid intima-media thickness and arterial stiffness in hypertensive patients. J Hum Hypertens 24:492-494.
44. Young TK, Bjerregaard P, Dewailly É, Risica PM, Jørgensen ME, Ebbesson SE. 2007. Prevalence of obesity and its metabolic correlates among the circumpolar Inuit in 3 countries. Am J Public Health 97:691-695.